Measuring levels of proteins in eye fluid may accurately predict need for lifelong macular ...
Medical Xpress· 1 day agoIn a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found...
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
Zacks via Yahoo Finance· 6 hours agoA potential approval for the 16-week dosing regimen would provide a longer treatment interval and...
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related ...
Morningstar· 7 days agoKinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001 ...
2-Year Faricimab Results: 'Visual Gains With Fewer Injections'
Medscape· 4 days agoThe trials compared two dosing regimens of faricimab — including a personalized treatment interval...
NHS delays: Avoidable blindness fears over eye care waits
BBC News· 2 days agoA "tide of avoidable blindness" could sweep Wales if eye care services are not reformed, a...
EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic...
WFMZ Eastern Pennsylvania and Western New Jersey· 1 day agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration...
Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as...
Nature· 6 days agoThe inclusion criteria were age 50 years or older, treatment-naïve nAMD confirmed by multimodal retinal imaging (fluorescein angiography, indocyanine green angiography, and ...
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Zacks· 2 days agoFree Report) announced that its board of directors is willing to conduct a comprehensive review of strategic options and alternatives focused on maximizing shareholders’ value of the company ...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 6 days agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
AAVantgarde Announces the Appointment of Naveed Shams, M.D., Ph.D. as Chief Development and Medical...
Associated Press· 13 hours agoMILAN, ITALY / ACCESSWIRE / June 30, 2022 / AAVantgarde Bio, a biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV) ...
Yahoo Web Search
Trending Now
